Kymera Therapeutics (KYMR) Receivables - Other (2020 - 2025)

Kymera Therapeutics (KYMR) has reported Receivables - Other for 6 consecutive years, with $20.0 million the latest figure, recorded in Q1 2025.

• In Q1 2025, Receivables - Other rose 885.22% year-over-year to $20.0 million; the TTM figure through Mar 2025 stood at $20.0 million (up 885.22% YoY), while the FY2024 annual figure was $947000.0, down 75.08% from the prior year.
• Receivables - Other improved to $20.0 million in Q1 2025 per KYMR's latest filing, from $900000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $20.0 million in Q1 2025 and bottomed at $135000.0 in Q4 2021.
• Historically, Receivables - Other has averaged $3.2 million across 5 years, with a median of $2.0 million in 2024.
• Annual changes were most pronounced in 2021 — Receivables - Other tumbled 76.6% — and 2022, when it surged 1751.85%.
• Kymera Therapeutics' Receivables - Other stood at $135000.0 in 2021, then soared by 1751.85% to $2.5 million in 2022, then surged by 52.0% to $3.8 million in 2023, then sank by 76.32% to $900000.0 in 2024, then soared by 2122.22% to $20.0 million in 2025.
• Business Quant data shows KYMR's Receivables - Other at $20.0 million in Q1 2025, $900000.0 in Q4 2024, and $1.3 million in Q3 2024.